746 related articles for article (PubMed ID: 25173754)
1. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
Adedokun OJ; Sandborn WJ; Feagan BG; Rutgeerts P; Xu Z; Marano CW; Johanns J; Zhou H; Davis HM; Cornillie F; Reinisch W
Gastroenterology; 2014 Dec; 147(6):1296-1307.e5. PubMed ID: 25173754
[TBL] [Abstract][Full Text] [Related]
2. A review of infliximab use in ulcerative colitis.
Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
[TBL] [Abstract][Full Text] [Related]
3. Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis.
Brandse JF; van den Brink GR; Wildenberg ME; van der Kleij D; Rispens T; Jansen JM; Mathôt RA; Ponsioen CY; Löwenberg M; D'Haens GR
Gastroenterology; 2015 Aug; 149(2):350-5.e2. PubMed ID: 25917786
[TBL] [Abstract][Full Text] [Related]
4. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
5. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
[TBL] [Abstract][Full Text] [Related]
6. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
Seow CH; Newman A; Irwin SP; Steinhart AH; Silverberg MS; Greenberg GR
Gut; 2010 Jan; 59(1):49-54. PubMed ID: 19651627
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.
Panaccione R; Ghosh S; Middleton S; Márquez JR; Scott BB; Flint L; van Hoogstraten HJ; Chen AC; Zheng H; Danese S; Rutgeerts P
Gastroenterology; 2014 Feb; 146(2):392-400.e3. PubMed ID: 24512909
[TBL] [Abstract][Full Text] [Related]
9. Infliximab for induction and maintenance therapy for ulcerative colitis.
Rutgeerts P; Sandborn WJ; Feagan BG; Reinisch W; Olson A; Johanns J; Travers S; Rachmilewitz D; Hanauer SB; Lichtenstein GR; de Villiers WJ; Present D; Sands BE; Colombel JF
N Engl J Med; 2005 Dec; 353(23):2462-76. PubMed ID: 16339095
[TBL] [Abstract][Full Text] [Related]
10. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.
Fasanmade AA; Adedokun OJ; Olson A; Strauss R; Davis HM
Int J Clin Pharmacol Ther; 2010 May; 48(5):297-308. PubMed ID: 20420786
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: a Korean multicenter retrospective study.
Lee KM; Jeen YT; Cho JY; Lee CK; Koo JS; Park DI; Im JP; Park SJ; Kim YS; Kim TO; Lee SH; Jang BI; Kim JW; Park YS; Kim ES; Choi CH; Kim HJ;
J Gastroenterol Hepatol; 2013 Dec; 28(12):1829-33. PubMed ID: 23829336
[TBL] [Abstract][Full Text] [Related]
12. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
Warman A; Straathof JW; Derijks LJ
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.
Adedokun OJ; Xu Z; Padgett L; Blank M; Johanns J; Griffiths A; Ford J; Zhou H; Guzzo C; Davis HM; Hyams J
Inflamm Bowel Dis; 2013 Dec; 19(13):2753-62. PubMed ID: 24193155
[TBL] [Abstract][Full Text] [Related]
15. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.
Arias MT; Vande Casteele N; Vermeire S; de Buck van Overstraeten A; Billiet T; Baert F; Wolthuis A; Van Assche G; Noman M; Hoffman I; D'Hoore A; Gils A; Rutgeerts P; Ferrante M
Clin Gastroenterol Hepatol; 2015 Mar; 13(3):531-8. PubMed ID: 25117777
[TBL] [Abstract][Full Text] [Related]
16. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
Hyams J; Damaraju L; Blank M; Johanns J; Guzzo C; Winter HS; Kugathasan S; Cohen S; Markowitz J; Escher JC; Veereman-Wauters G; Crandall W; Baldassano R; Griffiths A;
Clin Gastroenterol Hepatol; 2012 Apr; 10(4):391-9.e1. PubMed ID: 22155755
[TBL] [Abstract][Full Text] [Related]
17. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
[TBL] [Abstract][Full Text] [Related]
18. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
Vande Casteele N; Jeyarajah J; Jairath V; Feagan BG; Sandborn WJ
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1814-1821.e1. PubMed ID: 30613004
[TBL] [Abstract][Full Text] [Related]
19. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
[TBL] [Abstract][Full Text] [Related]
20. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study.
Naviglio S; Lacorte D; Lucafò M; Cifù A; Favretto D; Cuzzoni E; Silvestri T; Pozzi Mucelli M; Radillo O; Decorti G; Fabris M; Bramuzzo M; Taddio A; Stocco G; Alvisi P; Ventura A; Martelossi S
J Pediatr Gastroenterol Nutr; 2019 Jan; 68(1):37-44. PubMed ID: 30211845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]